-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 24, Jiangsu Kangyuan Pharmaceutical submitted an application for the 3 types of imitation listing of sumatriptan naproxen sodium succinate tablets
.
As early as 2016, Kangyuan Pharmaceutical bought 13 new chemical drug clinical approvals from Nanjing Warwick Pharmaceutical Technology, including sumatriptan succinate naproxen sodium tablets.
It is reported that the transfer price of each clinical approval was 570 A total of 74.
1 million yuan was spent on the purchase of 13 new drug clinical approval documents
.
.
As early as 2016, Kangyuan Pharmaceutical bought 13 new chemical drug clinical approvals from Nanjing Warwick Pharmaceutical Technology, including sumatriptan succinate naproxen sodium tablets.
It is reported that the transfer price of each clinical approval was 570 A total of 74.
1 million yuan was spent on the purchase of 13 new drug clinical approval documents
.
Figure 1: The latest product status of Kangyuan Pharmaceutical
Source: CDE official website
Sumatriptan Naproxen Sodium Succinate Tablets is the first approved combination prescription preparation of triptans and anti-inflammatory analgesics, which relieve migraines through different pharmacological mechanisms of action
.
Sumatriptan is a selective 5-HT1 receptor subtype agonist, which can mediate the vasoconstriction of the human basilar artery and infarct meningeal vasculature; naproxen sodium is a non-steroidal anti-inflammatory drug that inhibits the synthesis of inflammatory mediators
.
.
Sumatriptan is a selective 5-HT1 receptor subtype agonist, which can mediate the vasoconstriction of the human basilar artery and infarct meningeal vasculature; naproxen sodium is a non-steroidal anti-inflammatory drug that inhibits the synthesis of inflammatory mediators
.
Sumatriptan naproxen sodium succinate was jointly developed by GlaxoSmithKline and Pozen.
It was approved by the FDA in 2008 for the treatment of acute migraine in adults.
The global sales of 49 million pounds in 2012 were awarded in 2015.
FDA approved for the treatment of acute migraine in pediatric patients
.
It was approved by the FDA in 2008 for the treatment of acute migraine in adults.
The global sales of 49 million pounds in 2012 were awarded in 2015.
FDA approved for the treatment of acute migraine in pediatric patients
.
Figure 2: Clinical situation of Sumatriptan Naproxen Sodium Succinate Tablets
Source: China Drug Clinical Trial Publicity Library of Meinenet
Nanjing Warwick Pharmaceutical Technology won the clinical approval in 2016, and currently no other companies have applied for clinical or marketing applications for this product
.
From the point of view of clinical indications, it will be used for adult migraine patients.
After the product is on the market, it will most likely be re-declared for children- related indications
.
.
From the point of view of clinical indications, it will be used for adult migraine patients.
After the product is on the market, it will most likely be re-declared for children- related indications
.
Figure 3: Competition status of 2021H1 anti-migraine preparations for oral administration
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Minai.
com, the market size of terminal anti-migraine preparations in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 2 billion yuan in 2020 .
It can be seen that injections have always accounted for more than 90% of the market share, and the competition for oral drugs is relatively slow
.
In 2021, in the terminal oral anti-migraine preparation market of public medical institutions in China, Tianmasu will occupy more than 70% of the market
.
com, the market size of terminal anti-migraine preparations in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 2 billion yuan in 2020 .
It can be seen that injections have always accounted for more than 90% of the market share, and the competition for oral drugs is relatively slow
.
In 2021, in the terminal oral anti-migraine preparation market of public medical institutions in China, Tianmasu will occupy more than 70% of the market
.
Source: CDE official website, Minet database
Note: The statistics are as of November 25.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
On November 24, Jiangsu Kangyuan Pharmaceutical submitted an application for the 3 types of imitation listing of sumatriptan naproxen sodium succinate tablets
.
As early as 2016, Kangyuan Pharmaceutical bought 13 new chemical drug clinical approvals from Nanjing Warwick Pharmaceutical Technology, including sumatriptan succinate naproxen sodium tablets.
It is reported that the transfer price of each clinical approval was 570 A total of 74.
1 million yuan was spent on the purchase of 13 new drug clinical approval documents
.
.
As early as 2016, Kangyuan Pharmaceutical bought 13 new chemical drug clinical approvals from Nanjing Warwick Pharmaceutical Technology, including sumatriptan succinate naproxen sodium tablets.
It is reported that the transfer price of each clinical approval was 570 A total of 74.
1 million yuan was spent on the purchase of 13 new drug clinical approval documents
.
Figure 1: The latest product status of Kangyuan Pharmaceutical
Source: CDE official website
Sumatriptan Naproxen Sodium Succinate Tablets is the first approved combination prescription preparation of triptans and anti-inflammatory analgesics, which relieve migraines through different pharmacological mechanisms of action
.
Sumatriptan is a selective 5-HT1 receptor subtype agonist, which can mediate the vasoconstriction of the human basilar artery and infarct meningeal vasculature; naproxen sodium is a non-steroidal anti-inflammatory drug that inhibits the synthesis of inflammatory mediators
.
.
Sumatriptan is a selective 5-HT1 receptor subtype agonist, which can mediate the vasoconstriction of the human basilar artery and infarct meningeal vasculature; naproxen sodium is a non-steroidal anti-inflammatory drug that inhibits the synthesis of inflammatory mediators
.
Sumatriptan naproxen sodium succinate was jointly developed by GlaxoSmithKline and Pozen.
It was approved by the FDA in 2008 for the treatment of acute migraine in adults.
The global sales of 49 million pounds in 2012 were awarded in 2015.
FDA approved for the treatment of acute migraine in pediatric patients
.
It was approved by the FDA in 2008 for the treatment of acute migraine in adults.
The global sales of 49 million pounds in 2012 were awarded in 2015.
FDA approved for the treatment of acute migraine in pediatric patients
.
Figure 2: Clinical situation of Sumatriptan Naproxen Sodium Succinate Tablets
Source: China Drug Clinical Trial Publicity Library of Meinenet
Nanjing Warwick Pharmaceutical Technology won the clinical approval in 2016, and currently no other companies have applied for clinical or marketing applications for this product
.
From the point of view of clinical indications, it will be used for adult migraine patients.
After the product is on the market, it will most likely be re-declared for children- related indications
.
.
From the point of view of clinical indications, it will be used for adult migraine patients.
After the product is on the market, it will most likely be re-declared for children- related indications
.
Figure 3: Competition status of 2021H1 anti-migraine preparations for oral administration
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Minai.
com, the market size of terminal anti-migraine preparations in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 2 billion yuan in 2020 .
It can be seen that injections have always accounted for more than 90% of the market share, and the competition for oral drugs is relatively slow
.
In 2021, in the terminal oral anti-migraine preparation market of public medical institutions in China, Tianmasu will occupy more than 70% of the market
.
com, the market size of terminal anti-migraine preparations in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 2 billion yuan in 2020 .
It can be seen that injections have always accounted for more than 90% of the market share, and the competition for oral drugs is relatively slow
.
In 2021, in the terminal oral anti-migraine preparation market of public medical institutions in China, Tianmasu will occupy more than 70% of the market
.
Source: CDE official website, Minet database
Note: The statistics are as of November 25.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
On November 24, Jiangsu Kangyuan Pharmaceutical submitted an application for the 3 types of imitation listing of sumatriptan naproxen sodium succinate tablets
.
As early as 2016, Kangyuan Pharmaceutical bought 13 new chemical drug clinical approvals from Nanjing Warwick Pharmaceutical Technology, including sumatriptan succinate naproxen sodium tablets.
It is reported that the transfer price of each clinical approval was 570 A total of 74.
1 million yuan was spent on the purchase of 13 new drug clinical approval documents
.
.
As early as 2016, Kangyuan Pharmaceutical bought 13 new chemical drug clinical approvals from Nanjing Warwick Pharmaceutical Technology, including sumatriptan succinate naproxen sodium tablets.
It is reported that the transfer price of each clinical approval was 570 A total of 74.
1 million yuan was spent on the purchase of 13 new drug clinical approval documents
.
Figure 1: The latest product status of Kangyuan Pharmaceutical
Source: CDE official website
Sumatriptan Naproxen Sodium Succinate Tablets is the first approved combination prescription preparation of triptans and anti-inflammatory analgesics, which relieve migraines through different pharmacological mechanisms of action
.
Sumatriptan is a selective 5-HT1 receptor subtype agonist, which can mediate the vasoconstriction of the human basilar artery and infarct meningeal vasculature; naproxen sodium is a non-steroidal anti-inflammatory drug that inhibits the synthesis of inflammatory mediators
.
.
Sumatriptan is a selective 5-HT1 receptor subtype agonist, which can mediate the vasoconstriction of the human basilar artery and infarct meningeal vasculature; naproxen sodium is a non-steroidal anti-inflammatory drug that inhibits the synthesis of inflammatory mediators
.
Sumatriptan naproxen sodium succinate was jointly developed by GlaxoSmithKline and Pozen.
It was approved by the FDA in 2008 for the treatment of acute migraine in adults.
The global sales of 49 million pounds in 2012 were awarded in 2015.
FDA approved for the treatment of acute migraine in pediatric patients
.
It was approved by the FDA in 2008 for the treatment of acute migraine in adults.
The global sales of 49 million pounds in 2012 were awarded in 2015.
FDA approved for the treatment of acute migraine in pediatric patients
.
Figure 2: Clinical situation of Sumatriptan Naproxen Sodium Succinate Tablets
Source: China Drug Clinical Trial Publicity Library of Meinenet
Nanjing Warwick Pharmaceutical Technology won the clinical approval in 2016, and currently no other companies have applied for clinical or marketing applications for this product
.
From the point of view of clinical indications, it will be used for adult migraine patients.
After the product is on the market, it will most likely be re-declared for children- related indications
.
Pharmaceutical medicine pharmaceutical companies business enterprises Children's Children's Children.
From the point of view of clinical indications, it will be used for adult migraine patients.
After the product is on the market, it will most likely be re-declared for children- related indications
.
Figure 3: Competition status of 2021H1 anti-migraine preparations for oral administration
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Minai.
com, the market size of terminal anti-migraine preparations in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 2 billion yuan in 2020 .
It can be seen that injections have always accounted for more than 90% of the market share, and the competition for oral drugs is relatively slow
.
In 2021, in the terminal oral anti-migraine preparation market of public medical institutions in China, Tianmasu will occupy more than 70% of the market
.
Hospital hospital hospitalcom, the market size of terminal anti-migraine preparations in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 2 billion yuan in 2020 .
It can be seen that injections have always accounted for more than 90% of the market share, and the competition for oral drugs is relatively slow
.
In 2021, in the terminal oral anti-migraine preparation market of public medical institutions in China, Tianmasu will occupy more than 70% of the market
.
Source: CDE official website, Minet database
Note: The statistics are as of November 25.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
